Fig. 6

Psammaplin-A enhances cisplatin-induced cell death in vivo. a Left panels Percentage of apoptotic LLC cells subjected to treatment with 1 μM cisplatin, 5 μM PSA or in combination with two drugs for 48 h, assessed by Annexin V Data are shown as mean ± sem (n ≥ 3 independent experiments). P-values are from Student’s t-test. *P < 0.05; **P < 0.01; ***P < 0.001; Right panel: Flow cytometry analysis of Annexine V in LLC cell line. The figure is a representative of three experiments with similar results. b Upper panel: Schematic model of the mice treatment; Lower panel: Effects on the growth of tumors derived from subcutaneous injection of LLC cells in C57BL/6 mice treated with 2.5 mg/kg cisplatin, 1 mg/kg PSA, alone or in combination. c Tumor weight graph after 24 days from subcutaneous injection of LLC cells in C57BL/6 mice treated with 2.5 mg/kg cisplatin, 1 mg/kg, alone or in combination. Data are shown as mean ± sem (n ≥ 3 independent experiments). P-values are from Student’s t-test. *P < 0.05. d Upper panel: Schematic model of the mice treatment; Tumor weight graph after 24 days from subcutaneous injection of A549 cells in NSG mice treated with 2.5 mg/kg cisplatin, 1 mg/kg PSA, alone or in combination. Data are shown as mean ± sem (n ≥ 3 independent experiments). P-values are from Student’s t-test. **P < 0.01. e Quantification and representative Ki67 IHC staining. Data are shown as mean ± sem (n ≥ 3 independent experiments). P-values are from Student’s t-test. *P < 0.05; ***P < 0.001